| Keywords: |
survival; cancer chemotherapy; cancer survival; treatment outcome; survival analysis; leukemia; treatment failure; prednisone; clinical trial; doxorubicin; treatment planning; unspecified side effect; note; gemcitabine; adjuvant therapy; radiation dose; chemotherapy, adjuvant; radiotherapy, adjuvant; antineoplastic agent; lymph nodes; dacarbazine; controlled clinical trial; lung toxicity; multiple cycle treatment; etoposide; randomized controlled trial; antineoplastic combined chemotherapy protocols; radiotherapy dosage; lung cancer; editorial; combination chemotherapy; cyclophosphamide; vincristine; practice guideline; pathology; radiation injury; chlormethine; procarbazine; vinblastine; hodgkin disease; radiation exposure; randomized controlled trials; neoplasms, radiation-induced; adjuvant chemotherapy; lymph node; bleomycin; medical practice; cancer relapse; epirubicin; risk reduction; coronary artery disease; ischemic heart disease; coronary disease
|
